PACAP38：偏头痛和丛集性头痛的新兴药物靶点。

PACAP38: Emerging Drug Target in Migraine and Cluster Headache.

机构信息

Danish Headache Center and Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Glostrup, Copenhagen, 2600, Denmark.

出版信息

Headache. 2017 May;57 Suppl 2:56-63. doi: 10.1111/head.13076.

DOI:10.1111/head.13076

PMID:28485845

Abstract

Here, we review the role of pituitary adenylate cyclase-activating peptide-38 (PACAP38) in migraine and cluster headache (CH). Mounting evidence implicates signaling molecule PACAP38 in the pathophysiology of migraine. Human provocation studies show PACAP38 induces migraine attacks in migraine patients without aura and marked and sustained dilation of extracerebral arteries. PACAP38 selectively targets the PAC receptor making this receptor a promising candidate for targeted migraine therapy. Randomized clinical trials are warranted to pursue this possible treatment pathway. PACAP38 provocation studies in CH could elucidate possible involvement of PACAP38 in CH pathophysiology and predict efficacy of PACAP38 antagonists in this primary headache.

摘要

在这里，我们回顾了垂体腺苷酸环化酶激活肽-38（PACAP38）在偏头痛和丛集性头痛（CH）中的作用。越来越多的证据表明，信号分子 PACAP38 参与了偏头痛的病理生理学。人体激发研究表明，PACAP38 会在无先兆偏头痛患者中引发偏头痛发作，并显著且持续地扩张颅外动脉。PACAP38 选择性地靶向 PAC 受体，这使得该受体成为偏头痛靶向治疗的有前途的候选药物。有必要进行随机临床试验来探索这种可能的治疗途径。在 CH 中进行 PACAP38 激发研究可以阐明 PACAP38 可能参与 CH 的病理生理学，并预测 PACAP38 拮抗剂在这种原发性头痛中的疗效。